WEST DES MOINES, IA--(NewMediaWire - Feb 4, 2016) - Spotlight Innovation Inc. (OTCQB: STLT) on February 3, 2016, filed a Form 8-K containing a Company Overview presentation it plans to present to prospective buyers of its shares, investors and current shareholders. The Company Overview presentation can be found on the Company's website at www.spotlightinnovation.com/investors.
Cris Grunewald, President and Chief Executive Officer of Spotlight Innovation, said, "We have made continued and meaningful advances over the past few months and believe that now is an appropriate time to increase our visibility with the investment community. We are most pleased with the progress we have made with our cancer and infectious disease platform biotechnologies, and we encourage investors and shareholders to review our updated investor presentation."
About Spotlight Innovation Inc.
Spotlight Innovation Inc. (OTCQB: STLT) identifies and acquires rights to innovative and proprietary platform technology candidates with a focus on cancer drugs and related treatment therapies, solutions for infectious disease, and other specialty and unique opportunities. Access to platform technology candidates is accomplished via our extensive relationships with many leading academic institutions and other sources. We provide value-added development capability and funding in order to accelerate development progress. When commercially significant benchmarks have been achieved, we will partner with proven market leaders via sale, out-license or strategic alliance. For more information, visit www.spotlightinnovation.com or follow us on www.twitter.com/spotlightinno.
News 
Market Data 
Discover 
